Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Regeneron Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Accounts payable
Accrued expenses and other current liabilities
Finance lease liabilities, current portion
Deferred revenue
Current liabilities
Long-term debt
Finance lease liabilities, excluding current portion
Deferred revenue
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Preferred Stock, par value $.01 per share; shares issued and outstanding: none
Class A Stock, convertible, par value $.001 per share
Common Stock, par value $.001 per share
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Treasury Stock, at cost
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


Overall, the liabilities and stockholders’ equity of the company demonstrate a general upward trend over the observed period, though with some fluctuations. Total liabilities increased significantly from March 2021 to December 2021, and continued to grow, albeit at a slower pace, through December 2025. Stockholders’ equity also exhibited a consistent increase throughout the period, contributing to a substantial rise in total liabilities and equity.

Current Liabilities
Current liabilities experienced considerable volatility. A peak was observed in June 2021, followed by a decline and then another increase reaching a high in December 2023. A further increase occurred in December 2024, before decreasing slightly in the final two periods. The primary drivers of these fluctuations appear to be changes in accrued expenses and other current liabilities, and accounts payable.
Accounts Payable
Accounts payable showed a fluctuating pattern. It decreased from March 2021 to September 2021, then increased to December 2021. A subsequent decrease occurred through September 2022, followed by a steady increase until December 2022. A decrease was observed in the first half of 2023, followed by a significant increase in December 2024, and a slight decrease in the final two periods. This suggests potential shifts in payment terms with suppliers or changes in purchasing volume.
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities generally increased from March 2021 to September 2021, then fluctuated before increasing significantly in September 2023. This item represents a substantial portion of current liabilities and appears to be a key driver of changes in the current liability balance. A decrease was observed in the final two periods.
Long-Term Debt
Long-term debt remained remarkably stable throughout the entire period, showing minimal variation. This indicates a consistent debt management strategy with no significant new borrowings or repayments.
Noncurrent Liabilities
Noncurrent liabilities generally increased over the period, driven primarily by increases in other noncurrent liabilities. The finance lease liabilities, excluding the current portion, remained constant after their introduction in March 2022. The increase in other noncurrent liabilities suggests potential long-term obligations or deferred compensation arrangements.
Stockholders’ Equity
Stockholders’ equity demonstrated a consistent upward trend. Retained earnings were the primary contributor to this growth, increasing steadily throughout the period. Additional paid-in capital also contributed to the increase, though to a lesser extent. Treasury stock consistently decreased, offsetting some of the gains from retained earnings and additional paid-in capital. Accumulated other comprehensive income (loss) fluctuated, with a notable loss in December 2021, and a shift to positive values in September 2024, but remained a relatively small component of total equity.

In conclusion, the company’s financial position strengthened over the analyzed period, characterized by increasing liabilities and a robust growth in stockholders’ equity. The fluctuations in current liabilities warrant further investigation to understand the underlying drivers, while the stability of long-term debt suggests a conservative approach to debt financing.